| Literature DB >> 29183252 |
Destin U Lenz1, Effie L Crutcher1, Elisa M Greene1,2.
Abstract
Sexual dysfunction is a bothersome side effect of several medications, though it has not yet been reported with the use of ledipasvir/sofosbuvir for the treatment of hepatitis C. However, sexual dysfunction is a potentially unrecognized side effect of ledipasvir/sofosbuvir that could result in nonadherence and treatment failure. We report a case of a 42-year-old man with a sudden onset of sexual dysfunction with the initiation of ledipasvir/sofosbuvir for the treatment of hepatitis C. The patient had no prior history or risk factors for the development of sexual dysfunction. His symptoms resolved upon discontinuation of ledipasvir/sofosbuvir after a successful 12-week course. Clinicians should be aware that sexual dysfunction is a possible side effect of ledipasvir/sofosbuvir and educate patients appropriately. Adherence should be emphasized as the risks of untreated hepatitis C virus far outweigh transient sexual dysfunction.Entities:
Keywords: Harvoni®; hepatitis C virus; ledipasvir/sofosbuvir; sexual dysfunction
Mesh:
Substances:
Year: 2017 PMID: 29183252 DOI: 10.1177/0897190017744421
Source DB: PubMed Journal: J Pharm Pract ISSN: 0897-1900